Business Context and Reporting Period
Company: Eastman Kodak Company
Filing Type: Form 8-K (Current Report)
Date of Report: November 30, 1994
Reporting Period: The filing reports on events occurring through November 30, 1994, and includes restated financial data for the fiscal year ended December 31, 1993, to reflect the divestiture of non-imaging health businesses.
Kodak is executing a strategic refocus on consumer and commercial imaging businesses. This filing details the completion of major divestitures of its non-imaging health operations, including the Clinical Diagnostics Division and the do-it-yourself products business of L&F Products. Financial data for 1993 has been restated to exclude these discontinued operations.
Key Financial Metrics (Fiscal Year 1993)
| Metric | Amount (in millions) |
|---|---|
| Sales from Continuing Operations | $12,670 |
| Earnings from Continuing Operations (Before extraordinary items and accounting changes) |
$644 |
| Net Earnings (Loss) (Includes $2.17B accounting charge) |
$(1,515) |
| Primary Earnings Per Share (Continuing operations, pre-accounting changes) |
$1.95 |
| Primary Earnings Per Share (Net loss) |
$(4.62) |
| Total Assets | $18,810 |
| Long-Term Borrowings | $6,727 |
| Cash and Cash Equivalents | $1,635 |
| Operating Cash Flow | $2,353 |
Material Changes and Divestitures
Completed Divestitures (Effective Nov 30, 1994):
- Clinical Diagnostics Division: Sold to Johnson & Johnson for $1.008 billion in cash.
- L&F Products "Do-It-Yourself" Business: Sold to Forstmann Little & Co. for $700 million in cash.
Other Recent Divestitures (Completed in 1994):
- Sterling Winthrop Pharmaceutical Business: Sold to Sanofi for $1.675 billion (Oct 1, 1994).
- Sterling Winthrop Consumer Health Business: Sold to SmithKline Beecham for $2.925 billion (Nov 2, 1994).
- Eastman Chemical Company: Spun off to shareholders on Dec 31, 1993.
Financial Impact of Accounting Changes: The 1993 net loss of $1.515 billion was primarily driven by a non-cash, after-tax charge of $2.17 billion resulting from the adoption of SFAS No. 106 (Postretirement Benefits) and SFAS No. 112 (Postemployment Benefits). Excluding this charge, earnings from continuing operations were $644 million.
Segment Performance (1993)
- Consumer Imaging: Sales of $5.292 billion; Operating earnings of $931 million (17.6% margin).
- Commercial Imaging: Sales of $7.382 billion; Operating earnings of $317 million (4.3% margin).
Both segments faced headwinds from foreign currency fluctuations and lower effective selling prices, though unit volumes increased slightly.
Outlook, Risks, and Management Commentary
Management Commentary: Management emphasizes the strategic shift to imaging businesses. The divestitures of health and chemical businesses are intended to streamline operations. Restructuring costs of $495 million were incurred in 1993 to reduce worldwide employment by approximately 9,000 to 10,000 positions. Operating cash flows are projected to be adequate to support operations, capital expenditures, and dividends in 1994.
Debt and Liquidity: The company has an unused $2.5 billion revolving credit facility. In October 1994, Kodak announced a tender offer for up to $4.8 billion of long-term debt; $2.7 billion was tendered. This paydown program is expected to result in an extraordinary charge of approximately $160 million in the fourth quarter of 1994, along with losses from unwinding interest rate derivatives.
Risks and Contingencies:
- Environmental: Kodak is subject to significant environmental regulations (RCRA, Superfund, Clean Air Act). While $84 million was accrued for remediation at year-end 1993, future costs for the Kodak Park site in Rochester cannot be reasonably estimated yet.
- Legal: The company is involved in various lawsuits and environmental investigations, though management does not expect any single matter to be material.
- Market Competition: Strong global competition exists in both consumer and commercial imaging markets, with pressure on selling prices.
Investor Verification Checklist
- Divestiture Proceeds: Verify the receipt of cash proceeds from the Johnson & Johnson ($1.008B) and Forstmann Little ($700M) transactions.
- Debt Reduction: Confirm the final amount of debt retired via the October 1994 tender offer and the associated extraordinary charges in Q4 1994.
- Restructuring Execution: Monitor the progress of the workforce reduction program (targeting ~10,000 jobs) and the closure of the German facility.
- Environmental Liabilities: Track updates on the RCRA Facility Assessment for the Kodak Park site and potential future remediation costs.
- Segment Margins: Watch for trends in operating margins for Consumer and Commercial Imaging segments, specifically regarding pricing pressure and foreign currency impacts.